Fig. 7: TTK silencing increases the sensitivity of ovarian cancer to cisplatin through the mTOR/autophagy pathway. | Cell Death & Disease

Fig. 7: TTK silencing increases the sensitivity of ovarian cancer to cisplatin through the mTOR/autophagy pathway.

From: TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway

Fig. 7

A CAOV3 and OV90 cells transfected with NC or siTTK2 were treated with 1 or 2 μg/ml CDDP for 48 h. The relative protein levels of p-mTOR, mTOR, LC3-I/II and TTK were detected using western blotting. B, C CAOV3 and OV90 cells with or without TTK knockdown were treated with 1 or 2 μg/ml CDDP alone or in combination with 100 nM rapamycin. Cell viability (B) and the colony formation ability (C) were detected. D−F CAOV3 and OV90 cells transfected with NC or siTTK2 were treated with 2 or 4 μg/ml CDDP for 24 h and then treated in combination with or without 100 nM rapamycin for 24 h. D, E The protein levels of cleaved PARP and cleaved caspase-3 were evaluated using western blotting. F Flow cytometry was performed to detect apoptotic cells (data are mean ± SEM, #P > 0.05, *P < 0.05, **P < 0.01, n = 3).

Back to article page